MedTrace Logo

FOLFIRINOX Induction Chemotherapy for Synchronous Liver Metastases

NCT07467434 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 550

Last updated 2026-03-12

No results posted yet for this study

Summary

SYNCHRONOX is a multicenter cohort (retrospective then prospective) intending to include 550 patients with mid or low rectal adenocarcinoma (pMMR, T3-T4 and/or N+) and resectable synchronous liver metastases, treated upfront with at least two cycles of induction FOLFIRINOX chemotherapy. The primary objective is to determine, at 18 months, the R0 resection rate of both tumor sites (rectum and liver), while secondary objectives focus on 3 year overall and progression free survival, radiological and pathological responses, postoperative morbidity and mortality, and comparison of the different surgical strategies after FOLFIRINOX.

Conditions

  • Rectal Cancer
  • Synchronous Liver Metastases
  • Antineoplastic Combined Chemotherapy Protocols
  • Surgical Therapy

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2030-10-31
Completion
2034-04-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07467434 on ClinicalTrials.gov